LNTH Lantheus Holdings Inc

Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company’s Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021.

The presentation will be made available for the duration of conference.

Details for the ASCO presentation are as follows:

Session Title: Poster Session: Genitourinary Cancer – Prostate, Testicular and Penile

Title: PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.

Presenter: Frederic Pouliot, M.D., Ph.D., F.R.C.S.C., Centre Hospitalier Universitaire (CHU) de Québec-Université Laval

Abstract No: 5023

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA® for the treatment of certain rare neuroendocrine tumors; and RELISTOR® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, please visit .

EN
21/05/2021

Underlying

LNTHLantheus Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.42
ZBH ZIMMER BIOMET H...
OC OWENS CORNING ... (+28)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ZBH ZIMMER BIOMET HOLDINGS INC.
OC OWENS CORNING
WHR WHIRLPOOL CORPORATION
CBT CABOT CORPORATION
LNG CHENIERE ENERGY INC.
VC VISTEON CORPORATION
SM SM ENERGY COMPANY
EVEREST RE GROUP LTD.
NWL NEWELL BRANDS INC
LNTH LANTHEUS HOLDINGS INC
KRO KRONOS WORLDWIDE INC.
IOSP INNOSPEC INC.
HY HYSTER-YALE MATERIALS HANDLING INC. CLASS A
GLPI GAMING AND LEISURE PROPERTIES INC.
DECK DECKERS OUTDOOR CORPORATION
CHH CHOICE HOTELS INTERNATIONAL INC.
BCC BOISE CASCADE CO.
APD AIR PRODUCTS AND CHEMICALS INC.
CHE CHEMED CORPORATION
COLM COLUMBIA SPORTSWEAR COMPANY
TNC TENNANT COMPANY
WSO WATSCO INC.
BXC BLUELINX HOLDINGS
FTV FORTIVE CORP.
BCBP BCB BANCORP INC.
BBWI BATH & BODY WORKS INC
AESI NEW ATLAS HOLDCO INC
BGC BGC GROUP INC
02/18/26 February 18, 2026 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference...

Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 26, 2026, to discuss its financial and operating results for the fourth quarter and full year of 2025. To access the conference call or webcast, participants should register online at . To avoid delays, we encourage participants to register fifteen minutes ahead of the sche...

February 12, 2026 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.42
NUE Nucor Corporati...
PKG Packaging Corpo... ... (+35)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

NUE NUCOR CORPORATION
PKG PACKAGING CORPORATION OF AMERICA
SCCO SOUTHERN COPPER CORPORATION
PAA PLAINS ALL AMERICAN PIPELINE L.P.
LXU LSB INDUSTRIES INC.
LNTH LANTHEUS HOLDINGS INC
KMB KIMBERLY-CLARK CORPORATION
JYNT JOINT CORP
HUBB HUBBELL INCORPORATED CLASS B
HRL HORMEL FOODS CORPORATION
GPRK GEOPARK
DAN DANA INCORPORATED
CVS CVS HEALTH CORPORATION
BLL BALL CORPORATION
ASH ASHLAND GLOBAL HOLDINGS INC.
ACD ADECOAGRO S.A.
ADM ARCHER-DANIELS-MIDLAND COMPANY
NYT NEW YORK TIMES COMPANY CLASS A
ATRO ASTRONICS CORPORATION
DRI DARDEN RESTAURANTS INC.
SXC SUNCOKE ENERGY INC.
CDZI CADIZ INC.
TEC TECHNIPFMC PLC
RNGR RANGER ENERGY SERVICES
CSTL CASTLE BIOSCIENCES
APA APA CORPORATION
AKLCP ONTO INNOVATION INC.
PR KOLTSOVO AIRPORT
BG PERMIAN RESOURCES CORPORATION
PRMB BUNGE LIMITED
USAU PRIMO BRANDS CORP
UAN US GOLD CORP
DFTX ARCADIAN PARTNERS LP PFD
VXX DEFINIUM THERAPEUTICS INC.
IPATH SERIES B S&P 500 VIX SHORT-TERM FUTURES ETN
01/27/26 January 27, 2026 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologie...

Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced it has completed the previously announced sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. (collectively, “SHINE”). Under the terms of the agreem...

January 2, 2026 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Present Florbetaben F 18 Data at CTAD 2025

Lantheus to Present Florbetaben F 18 Data at CTAD 2025 BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new florbetaben F18 data at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, taking place December 1-4, in San Diego, CA. Presentation details are as follows: Poster Presentation Date & Time: Wednesday, December 3, 2025; 7:15...

November 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch